References
- Monika SK, Wolfgang M, Hans-Christian K. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 2007;59:427–43
- Effing JJ, Gruhlk EA, Godbey KJ, Welsing W. Transdermal device for the delivery of flurbiprofen. Patent: W009733205-A.1997.1.3
- Fang JY, Hwang TL, Leu YL. Effect of enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogels. Int J Pharm 2003;250:313–25
- Bhaskar K, Anbu1 J, Ravichandiran1 V, Venkateswarlu V. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 2009;8:6. doi: 10.1186/1476-511X-8-6
- Vega E, Egea MA, Garduño-Ramírez ML, et al. Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-β-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy. Colloids Surf B: Biointerfaces 2013;110:339–46
- Tomonobu U, Yuiko M, Akiko M, et al. Transdermal delivery of flurbiprofen from surfactant-based vesicles: particle characterization and the effect of water on in vitro transport. Int J Pharm 2014;464:75–84
- Seetapan N, Bejrapha P, Srinuanchai W, Ruktanonchai UR. Rheological and morphological characterizations on physical stability of gamma-oryzanolloaded solid lipid nanoparticles (SLNs). Micron 2010;41:51–8
- Yue Y, Zhou HF, Liu GL, et al. The advantages of a novel CoQ10 delivery system in skin photo-protection. Int J Pharm 2010;392:57–63
- Pardeike J, Schwabea K, Müller RH. Influence of nanostructured lipid carriers (NLC) on the physical properties of the Cutanova Nanorepair Q10 cream and the in vivo skin hydration effect. Int J Pharm 2010;396:166–73
- Guo CY, Yang CF, Li QL, et al. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 2012;430:292–8
- Fan XC, Chen JJ, Shen Q. Docetaxel–nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery. Int J Pharm 2013;458:296–304
- Han F, Li SM. Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen. Drug Dev Ind Pharm 2008;34:453–8
- Gonza Lez-mira E, Nikollic S, Garcia ML, et al. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci 2011;100:242–52
- Han F, Yin R, Che X, et al. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm 2012;439:349–57
- Draize J, Woodard G, Calvery H. Methods for the study of irritation and toxicity of substances topically applied to skin and mucous membranes. J Pharmacol Exp Ther 1944;82:377–90
- Verneer BJ. Skin irritation and sensitization. J Control Release 1991;15:261–5
- Joshi MD, Patravale VB. Formulation and evaluation of nanostructured lipid carrier (NLC) based gel of valdecoxib. Drug Dev Ind Pharm 2006;32:911–18
- Tang X, Lin Z, Cai W, et al. Anti-inflammatory effect of 3-acetylaconitine. Acta Pharmacol Sin 1984;5:85–9
- Higaki K, Asai M, Suyama T. Estimation of intradermal disposition kinetics of drugs: II. factors determining penetration of drugs from viable skin to muscular layer. Int J Pharm 2002;239:129–41
- Higaki K, Nakayama K, Suyama T, et al. Enhancement of topical delivery of drugs via direct penetration by reducing blood flow rate in skin. Int J Pharm 2008;2:227–33